Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12615000460505
ACTRN12615000460505
Terminated
Phase 1

In people with treatment resistant schizophrenia, is sodium benzoate a tolerated and acceptable augmentation strategy: a phase Ib/II study.

niveristy of Otago0 sites1 target enrollmentMay 12, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSchizophreniaTreatment ResistanceMental Health - Schizophrenia

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
niveristy of Otago
Enrollment
1
Status
Terminated
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 12, 2015
End Date
June 1, 2016
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niveristy of Otago

Eligibility Criteria

Inclusion Criteria

  • •1\.A clinical diagnosis of Schizophrenia, confirmed by a structured diagnostic interview.
  • •2\.Have a body mass index between 18 and 35 (that is, not underweight or markedly overweight)
  • •3\.Have had no major change in their symptoms for three months.
  • •4\.Have moderate to severe current symptom

Exclusion Criteria

  • •1\.You are pregnant or are intending to become pregnant.
  • •2\.Have a history of alcohol or drug dependance.
  • •3\.Have a history of epilepsy, head injury, or a neurological disorder.
  • •4\.If participating in the trial would place you at unacceptable risk.
  • •5\.If you are considered highly likely to not take any medications, as part of the study or not.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Therapie Resistentie Voorspellen bij SchizofrenieSchizophrenia, treatment resistance, psychosis, schizofrenie, therapie resistentie, psychose
NL-OMON21525Amsterdam UMC, University of Amsterdam100
Completed
Not Applicable
Predicting Treatment Resistance in Schizophreniafirst episode psychosisschizophrenia10039628
NL-OMON48828Academisch Medisch Centrum120
Terminated
Phase 3
Augmentation of antipsychotic medication with anticonvulsant in the management of treatment resistant schizophreniaSchizophreniaMental and Behavioural Disorders
ISRCTN77257074King's College London371
Completed
Not Applicable
Assertive Outreach for people with schizophrenia
DRKS00003351euphana Universität Lüneburg341
Completed
Not Applicable
Pilot study for a new treatment of schizophrenia: a double-blind crossover transcranial magnetic stimulatio
ISRCTN93378085Record Provided by the NHSTCT Register - 2007 Update - Department of Health12